Status:
COMPLETED
Breast Cancer Survivors Who Experience Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)
Lead Sponsor:
Mayo Clinic
Conditions:
Anatomic Stage 0 Breast Cancer AJCC v8
Anatomic Stage I Breast Cancer AJCC v8
Eligibility:
FEMALE
18+ years
Brief Summary
This study evaluates the effectiveness of a cognitive behavioral multicomponent treatment program in improving pain, mood, and functioning while reducing medication non-adherence in breast cancer pati...
Detailed Description
PRIMARY OBJECTIVES: I. To evaluate the effectiveness of a Multidisciplinary Pain Program for AIMSS, specifically determine the impact of the program on level of pain, functional status, and adherence...
Eligibility Criteria
Inclusion
- Patients are 18 years old or more.
- A breast cancer survivor ECOG =\< 2, stage 0-III HR+ who is experiencing musculoskeletal symptoms associated with aromatase inhibitors intake
- Patients must be at least 6 months on aromatase inhibitors and for no more than 7 years
Exclusion
- Breast cancer survivor patients that are not in aromatase inhibitor treatment or have less than 6 months of treatment or more than 7 years of treatment.
- Asymptomatic patients
- Patients less than 18 years old
- Patient that are not being followed as a Mayo Clinic patient
- Patients with stage IV breast carcinoma
- Patients that are HR -
- Patients that are ECOG 3 or more
Key Trial Info
Start Date :
July 12 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 27 2025
Estimated Enrollment :
105 Patients enrolled
Trial Details
Trial ID
NCT06106282
Start Date
July 12 2023
End Date
October 27 2025
Last Update
October 31 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Florida
Jacksonville, Florida, United States, 32224-9980